Altimmune To Present New Data On The Lipidomic Profile In Subjects Treated With Pemvidutide At The Liver Meeting 2024
Portfolio Pulse from Benzinga Newsdesk
Altimmune, Inc. will present new data on the lipidomic profile of subjects treated with pemvidutide at The Liver Meeting 2024. The data shows reductions in atherogenic and cardio-inflammatory lipids from a Phase 1b study. A Phase 2b trial is ongoing with results expected in Q2 2025.
October 15, 2024 | 12:26 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Altimmune will present data showing reductions in harmful lipids from a Phase 1b study of pemvidutide at The Liver Meeting 2024. This could positively impact investor sentiment as the company progresses with its Phase 2b trial.
The presentation of positive data on pemvidutide at a major conference could boost investor confidence in Altimmune's pipeline. The ongoing Phase 2b trial and expected results in 2025 add to the potential for future growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90